JK

Jerry Karabelas

Lead Independent Director at REGENXBIO

Dr. Karabelas has held a number of senior executive positions in major pharmaceutical companies, including Head of Healthcare and CEO of Worldwide Pharmaceuticals for Novartis AG, where he had full responsibility for Novartis Pharma and Ciba Vision, as well as strategic and operational leadership of R&D. Dr. Karabelas were also Executive Vice President of SmithKline Beecham with responsibility for U.S. and European operations, regulatory, and strategic marketing. Most recently, Dr. Karabelas has chaired the boards of several biopharmaceutical companies, including Human Genome Sciences, Inc., Vanda Pharmaceuticals, Inc., SkyePharma PLC, and Polyphor, AG. He currently chairs the board of Inotek and is a venture partner at Apple Tree Partners. Dr. Karabelas holds a Ph.D. in Pharmacokinetics from the Massachusetts College of Pharmacy.


Org chart

This person is not in the org chart


Teams

This person is not in any teams


Offices

This person is not in any offices


REGENXBIO

4 followers

REGENXBIO is seeking to improve lives through the curative potential of gene therapy. Our NAV® Technology Platform has ushered in a new era of gene therapy innovation.


Industries

Employees

201-500

Links